The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
September 14th 2024
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
Dr D'Abreo on Patient Consideration When Choosing Treatments in HER2+ Breast Cancer
January 19th 2024Nina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.
Exploratory Analyses of KATHERINE Trial Inform Adjuvant T-DM1 Use in HER2+ Breast Cancer
December 18th 2023Maria Hafez, MD, spotlights the KATHERINE trial in HER2-positive breast cancer, expanding on the respective toxicity profiles of T-DM1 and trastuzumab that were identified in an exploratory safety analysis of the trial; updated outcomes with T-DM1 in those with residual invasive disease after neoadjuvant treatment and surgery; and more.
Neoadjuvant KN026 Plus Docetaxel Demonstrates Early Activity in HER2+ Breast Cancer
The novel bispecific antibody KN026 and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive early or locally advanced breast cancer.
T-DXd Continues to Show Robust CNS Activity in HER2+ Breast Cancer With Brain Metastases
December 13th 2023Javier Cortés, MD, PhD, expands on the importance of investigating the central nervous system activity of trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases; key efficacy data from the pooled analysis of the agent in the DESTINY-Breast01, -02 and -03 trials; and more.
Zanidatamab Triplet Shows Positive PFS Outcomes in HR+/HER2+ Metastatic Breast Cancer
Zanidatamab in combination with palbociclib and fulvestrant resulted in positive progression-free survival outcomes and exhibited an acceptable safety profile in patients with hormone receptor–positive, HER2-positive metastatic breast cancer.
Atezolizumab Plus Neoadjuvant HP/Chemo Does Not Significantly Improve pCR in HER2+ Breast Cancer
The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.
PFS Benefit Observed With Tucatinib Plus T-DM1 in Previously Treated HER2+ Metastatic Breast Cancer
December 6th 2023The addition of tucatinib to ado-trastuzumab emtansine (T-DM1) significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer, including those with brain metastases.
BDC-1001 Plus Pertuzumab Is Under Exploration in HER2+ Breast Cancer
The phase 2 BBI-20231001 trial evaluating the Boltbody immune-stimulating antibody conjugate BDC-1001 with or without pertuzumab in patients with HER2-positive breast adenocarcinoma is open for enrollment in the United States, France, Italy, and Spain.
EG12014 Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers
EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union for the treatment of patients with HER2-positive breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the EU.
Frontline Pyrotinib Plus Trastuzumab and Docetaxel Improves PFS in HER2+ Metastatic Breast Cancer
November 8th 2023The addition of pyrotinib to trastuzumab and docetaxel led to a significant improvement in progression-free survival compared with placebo plus trastuzumab and docetaxel in patients with newly diagnosed, HER2-positive metastatic breast cancer.
Neoadjuvant Inetetamab Combo Shows Efficacy, Tolerability in Locally Advanced HER2+ Breast Cancer
The combination of inetetamab, pertuzumab, paclitaxel, and carboplatin elicited responses with an acceptable safety profile when administered as neoadjuvant treatment in patients with locally advanced HER2-positive breast cancer.
Trastuzumab Duocarmazine Provides Numerical OS Benefit in Pretreated HER2+ Breast Cancer
Treatment with vic-trastuzumab duocarmazine demonstrated a trend toward numerically prolonged overall survival compared with physician’s choice of treatment in patients with pretreated HER2-positive metastatic breast cancer.